Pitfalls of pharmacoepidemiology.
作者信息
Skegg D C
出版信息
BMJ. 2000 Nov 11;321(7270):1171-2. doi: 10.1136/bmj.321.7270.1171.
Abstract
摘要
相似文献
1
Pitfalls of pharmacoepidemiology.
BMJ. 2000 Nov 11;321(7270):1171-2. doi: 10.1136/bmj.321.7270.1171.
2
Pitfalls of pharmacoepidemiology.
BMJ. 2000 Dec 16;321(7275):1528-9.
3
Venous thromboembolism and oral contraceptives.
Lancet. 1999 Oct 23;354(9188):1469; author reply 1469-70. doi: 10.1016/S0140-6736(05)77605-4.
4
Venous thromboembolism and oral contraceptives.
Lancet. 1999 Oct 23;354(9188):1470. doi: 10.1016/S0140-6736(05)77607-8.
5
Venous thromboembolism and oral contraceptives.
Lancet. 1999 Oct 23;354(9188):1469; author reply 1469-70. doi: 10.1016/S0140-6736(99)90187-3.
6
Oral contraceptives, venous thromboembolism, and the courts.
BMJ. 2002 Sep 7;325(7363):504-5. doi: 10.1136/bmj.325.7363.504.
7
[Risk of venous thromboembolism among users of third-generation oral contraceptives].
Presse Med. 2001 Mar 24;30(11):535-6.
8
Do third-generation oral contraceptives (OCs) increase the risk of venous thrombosis?
J Fam Pract. 2001 Oct;50(10):893.
9
The third generation pill controversy ("continued").
BMJ. 2001 Jul 21;323(7305):119-20. doi: 10.1136/bmj.323.7305.119.
10
[Oral contraceptives and thrombosis].
Ugeskr Laeger. 2001 Aug 20;163(34):4549-53.
引用本文的文献
1
Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review.
BMC Med Res Methodol. 2019 Mar 11;19(1):53. doi: 10.1186/s12874-019-0695-y.
2
A pathway to improved prospective observational post-authorization safety studies.
Drug Saf. 2012 Sep 1;35(9):711-24. doi: 10.1007/BF03261968.
3
An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.
Drug Saf. 2006;29(2):175-81. doi: 10.2165/00002018-200629020-00008.
4
Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?
Drug Saf. 2002;25(13):893-902. doi: 10.2165/00002018-200225130-00001.
5
Oral contraceptives, venous thromboembolism, and the courts.
BMJ. 2002 Sep 7;325(7363):504-5. doi: 10.1136/bmj.325.7363.504.
6
Pitfalls of pharmacoepidemiology.
BMJ. 2000 Nov 25;321(7272):1352. doi: 10.1136/bmj.321.7272.1352.
本文引用的文献
1
Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis.
BMJ. 2000 Nov 11;321(7270):1190-5. doi: 10.1136/bmj.321.7270.1190.
2
Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database.
BMJ. 2000;321(7259):477-9. doi: 10.1136/bmj.321.7259.477.
3
Third generation oral contraceptives.
BMJ. 2000 Jul 22;321(7255):190-1. doi: 10.1136/bmj.321.7255.190.
4
HMG-CoA reductase inhibitors and the risk of fractures.
JAMA. 2000 Jun 28;283(24):3205-10. doi: 10.1001/jama.283.24.3205.
5
A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives.
Br J Clin Pharmacol. 2000 Jun;49(6):580-90. doi: 10.1046/j.1365-2125.2000.00198.x.
6
The UK General Practice Research Database.
Lancet. 1997 Oct 11;350(9084):1097-9. doi: 10.1016/S0140-6736(97)04248-7.
7
A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
N Engl J Med. 1998 Sep 10;339(11):719-24. doi: 10.1056/NEJM199809103391102.
8
Use of the UK General Practice Research Database for pharmacoepidemiology.
Br J Clin Pharmacol. 1998 May;45(5):419-25. doi: 10.1046/j.1365-2125.1998.00701.x.
9
Calcium-channel blockers and risk of cancer.
Lancet. 1997 Feb 22;349(9051):525-8. doi: 10.1016/S0140-6736(97)80084-0.
10
Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Lancet. 1997 Jan 11;349(9045):83-8. doi: 10.1016/s0140-6736(96)07496-x.
Zotero 插件